secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001104659-23-001710
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix: 2022 Dextenza revenue est. $50.2M (+20% YoY); cash $102.3M; pipeline on track
--------------------------------------------------------------------------------

- Dextenza net product revenue: Q4 2022 est. $13.6M (14% seq., 11% YoY); FY2022 est. $50.2M (20% YoY).
- Preliminary cash and equivalents $102.3M as of Dec 31, 2022; sufficient to fund operations through mid-2024.
- OTX-TKI wet AMD Phase 1: 9- and 10-month data at Angiogenesis Feb 2023; potential Phase 2/3 start Q3 2023 subject to funding.
- Phase 1 diabetic retinopathy trial initiated Dec 2022; OTX-TIC glaucoma Phase 2 top-line data expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923001710/0001104659-23-001710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923001710/tm232417d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-001710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer